A New Standard of Care for Advanced Lung Cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Chemokine Receptors in Peripheral Blood Mononuclear Cells as Predictive Biomarkers for Immunotherapy Efficacy in Non-Small Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2025
   Review
2. AMIGO2 attenuates innate cisplatin sensitivity by suppression of GSDME-conferred pyroptosis in non-small cell lung cancer.Journal of cellular and molecular medicine · 2023
   Article
3. Comprehensive analysis of the expression and prognosis for RBR E3 ubiquitin ligases in lung adenocarcinoma.Thoracic cancer · 2022
   Article
4. The prognostic value of USP14 and PSMD14 expression in non-small cell lung cancer.Annals of translational medicine · 2021
   Article
5. PSMD7 downregulation suppresses lung cancer progression by regulating the p53 pathway.Journal of Cancer · 2021
   Article
6. Effect of pemetrexed on the efficacy, toxic reaction, and survival rate of patients with EGFR-TKI resistant moderate and advanced lung cancer.American journal of translational research · 2021
   Article
7. RBBP6 induces non-small cell lung cancer cell proliferation and high expression is associated with poor prognosis.Oncology letters · 2020
   Article
8. Upregulation of deubiquitinase PSMD14 in lung adenocarcinoma (LUAD) and its prognostic significance.Journal of Cancer · 2020
   Article
9. Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer.Seminars in immunopathology · 2019
   Review
10. Recent Trends in Potential Therapeutic Applications of the Dietary Flavonoid Didymin.Molecules (Basel, Switzerland) · 2018
    Review
11. CXCR4 Based Therapeutics for Non-Small Cell Lung Cancer (NSCLC).Journal of clinical medicine · 2018
    Review

Corrections and comments

• Comment on
  Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.2018

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as